AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...
3d
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Amgen and AstraZeneca are also investigating Tezspire in other conditions such as chronic spontaneous urticaria and ...
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
AstraZeneca is building a US$1.5 billion manufacturing facility in Tuas South, Singapore, which will create over 800 jobs.
DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback